MIM
Monashee Investment Management Portfolio holdings
AUM
$190M
This Quarter Return
+5.78%
1 Year Return
+42.84%
3 Year Return
+185.9%
5 Year Return
+237.5%
10 Year Return
+2,730.86%
AUM
$270M
AUM Growth
+$270M
(-1.9%)
Cap. Flow
+$1.6M
Cap. Flow
% of AUM
0.59%
Top 10 Holdings %
Top 10 Hldgs %
77.59%
Holding
68
New
41
Increased
2
Reduced
6
Closed
16
Top Buys
| 1 |
Invesco QQQ Trust
QQQ
|
$87.4M |
| 2 |
Gossamer Bio
GOSS
|
$8.31M |
| 3 |
Philip Morris
PM
|
$5.4M |
| 4 |
Corebridge Financial
CRBG
|
$4.92M |
| 5 |
argenx
ARGX
|
$4.24M |
Top Sells
| 1 |
Vanguard Total Stock Market ETF
VTI
|
$130M |
| 2 |
Hyperfine
HYPR
|
$3.89M |
| 3 |
American Tower
AMT
|
$3.83M |
| 4 |
Albertsons Companies
ACI
|
$3.34M |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$2.85M |
Sector Composition
| 1 | Healthcare | 18.97% |
| 2 | Financials | 2.55% |
| 3 | Consumer Staples | 2% |
| 4 | Materials | 1.3% |
| 5 | Energy | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Invesco QQQ Trust
QQQ
$364B
| $87.4M | 32.41% | +327,000 | New | +$87.4M |
|
|
2
Vanguard Total Stock Market ETF
VTI
$526B
| $85.1M | 31.55% | 474,000 -722,400 | -60% | -$130M |
|
|
3
Gossamer Bio
GOSS
$562M
| $8.31M | 3.08% | +693,477 | New | +$8.31M |
|
|
4
Philip Morris
PM
$260B
| $5.4M | 2% | +65,000 | New | +$5.4M |
|
|
5
Corebridge Financial
CRBG
$18.7B
| $4.92M | 1.83% | +250,000 | New | +$4.92M |
|
|
6
argenx
ARGX
$43.6B
| $4.24M | 1.57% | +12,000 | New | +$4.24M |
|
7
AN2 Therapeutics
ANTX
$30.1M
| $4.06M | 1.5% | 233,330 | – | – |
|
8
Sylvamo
SLVM
$1.86B
| $3.05M | 1.13% | +90,000 | New | +$3.05M |
|
|
SLGC
9
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $2.9M | 1.08% | 1,000,000 +75,000 | +8% | +$218K |
|
10
Compass Therapeutics
CMPX
$483M
| $2.81M | 1.04% | 1,230,441 | – | – |
|
11
Carnival Corp
CCL
$43.2B
| $2.56M | 0.95% | +364,666 | New | +$2.56M |
|
12
Dyne Therapeutics
DYN
$1.92B
| $2.54M | 0.94% | 200,000 -119,536 | -37% | -$1.52M |
|
13
Biohaven
BHVN
$1.63B
| $2.52M | 0.93% | +400,000 | New | +$2.52M |
|
14
Core & Main
CNM
$12.3B
| $2.5M | 0.93% | +110,000 | New | +$2.5M |
|
|
RVNC
15
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.3M | 0.85% | +85,000 | New | +$2.3M |
|
16
Akero Therapeutics
AKRO
$3.74B
| $2.21M | 0.82% | +65,000 | New | +$2.21M |
|
17
Pliant Therapeutics
PLRX
$101M
| $2.09M | 0.77% | +100,000 | New | +$2.09M |
|
18
Alignment Healthcare
ALHC
$3.24B
| $1.89M | 0.7% | +160,000 | New | +$1.89M |
|
|
KDNY
19
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.87M | 0.69% | 95,000 -145,000 | -60% | -$2.85M |
|
20
EyePoint Pharmaceuticals
EYPT
$797M
| $1.74M | 0.65% | +220,000 | New | +$1.74M |
|
21
DocGo
DCGO
$153M
| $1.74M | 0.64% | 175,000 -210,058 | -55% | -$2.08M |
|
22
Crescent Energy
CRGY
$2.43B
| $1.68M | 0.62% | +125,000 | New | +$1.68M |
|
23
Fulcrum Therapeutics
FULC
$351M
| $1.62M | 0.6% | +200,000 | New | +$1.62M |
|
24
SoFi Technologies
SOFI
$30.6B
| $1.56M | 0.58% | +320,000 | New | +$1.56M |
|
25
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.49M | 0.55% | 191,945 -8,055 | -4% | -$62.5K |
|